Determination of Serum Glycogen Synthase 3 Beta Levels in Patients with Heart Failure, a Novel Marker for Diagnosis and Defining Disease Severity?
Abstract Background Glycogen synthase kinase 3β (GSK3β) is an enzyme that has roles in the pathogenesis of heart failure (HF). We try to reveal serum GSK3β levels in types of HF. Objectives In this study, we evaluated serum GSK3β levels in HF patients. Also, we tried to elucidate any possible relati...
Gespeichert in:
Veröffentlicht in: | Arquivos brasileiros de cardiologia 2024, Vol.121 (11) |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 11 |
container_start_page | |
container_title | Arquivos brasileiros de cardiologia |
container_volume | 121 |
creator | Altunbas, Gokhan Kaplan, Mehmet Duzen, Veysel Kaya, Emin Erdem Gokdeniz, Hafize Gokce Taysi, Seyithan |
description | Abstract Background Glycogen synthase kinase 3β (GSK3β) is an enzyme that has roles in the pathogenesis of heart failure (HF). We try to reveal serum GSK3β levels in types of HF. Objectives In this study, we evaluated serum GSK3β levels in HF patients. Also, we tried to elucidate any possible relationship between serum GSK3β levels and disease severity among three different types of HF patients. Methods We performed a prospective study and enrolled 112 patients: 50 patients in heart failure with preserved ejection fraction (HFpEF) group, 30 patients in heart failure with mildly reduced ejection fraction (HFmrEF) group, and 32 patients in heart failure with reduced ejection fraction group (HFrEF). We also evaluated 50 healthy controls. Echocardiographic examinations were performed. We measured serum GSK-3β and N-terminal pro-B-type natriuretic peptide (NT-proBNP). We measured highly sensitive C-reactive protein (hs-CRP) levels and calculated neutrophil-lymphocyte ratio (NLR) platelets-to-lymphocyte ratio (PLR) from the hemogram count. Statistical significance was accepted p < 0.05. Results Serum GSK3β levels were significantly higher among patients with HF compared to healthy controls (median GSK3β levels; 117.26 (45.39 -223.85) vs 13.91 (5.6 -23.3) ng/mL, p |
doi_str_mv | 10.36660/abc.20240155i |
format | Article |
fullrecord | <record><control><sourceid>crossref</sourceid><recordid>TN_cdi_crossref_primary_10_36660_abc_20240155i</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_36660_abc_20240155i</sourcerecordid><originalsourceid>FETCH-LOGICAL-c79i-5d7d1cc89be6324df4c2b6b1bd69405bcb38bf8013861b02b676b49da92109ba3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EEqWwZT0fQIofiZOsELS0RSoPqV2wi2xn0hpaB9kuKL_BFxMeYjXSnXvP4hByzuhISCnppdJmxClPKcsye0AGTOZFkrKcHpIBpVImecGfj8lJCC-Ucp6LbEA-JxjR76xT0bYO2gaW6Pc7mG07067RwbJzcaMCgoAbjAoW-I7bANbBUz9BFwN82LiBOSofYarsdu_xAhQ8tH0R7pV_RQ9N62Fi1dq1wQZQroYJNtZZt-7jgN_8ZQ_2NnZXp-SoUduAZ393SFbT29V4niweZ3fj60Vi8tImWZ3XzJii1CgFT-smNVxLzXQty5Rm2mhR6KagTBSSadr_cqnTslYlZ7TUSgzJ6BdrfBuCx6Z683anfFcxWv0IrXqh1b9Q8QWke2tl</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Determination of Serum Glycogen Synthase 3 Beta Levels in Patients with Heart Failure, a Novel Marker for Diagnosis and Defining Disease Severity?</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>PubMed Central Open Access</source><creator>Altunbas, Gokhan ; Kaplan, Mehmet ; Duzen, Veysel ; Kaya, Emin Erdem ; Gokdeniz, Hafize Gokce ; Taysi, Seyithan</creator><creatorcontrib>Altunbas, Gokhan ; Kaplan, Mehmet ; Duzen, Veysel ; Kaya, Emin Erdem ; Gokdeniz, Hafize Gokce ; Taysi, Seyithan</creatorcontrib><description><![CDATA[Abstract Background Glycogen synthase kinase 3β (GSK3β) is an enzyme that has roles in the pathogenesis of heart failure (HF). We try to reveal serum GSK3β levels in types of HF. Objectives In this study, we evaluated serum GSK3β levels in HF patients. Also, we tried to elucidate any possible relationship between serum GSK3β levels and disease severity among three different types of HF patients. Methods We performed a prospective study and enrolled 112 patients: 50 patients in heart failure with preserved ejection fraction (HFpEF) group, 30 patients in heart failure with mildly reduced ejection fraction (HFmrEF) group, and 32 patients in heart failure with reduced ejection fraction group (HFrEF). We also evaluated 50 healthy controls. Echocardiographic examinations were performed. We measured serum GSK-3β and N-terminal pro-B-type natriuretic peptide (NT-proBNP). We measured highly sensitive C-reactive protein (hs-CRP) levels and calculated neutrophil-lymphocyte ratio (NLR) platelets-to-lymphocyte ratio (PLR) from the hemogram count. Statistical significance was accepted p < 0.05. Results Serum GSK3β levels were significantly higher among patients with HF compared to healthy controls (median GSK3β levels; 117.26 (45.39 -223.85) vs 13.91 (5.6 -23.3) ng/mL, p<0.001). Also, GSK3β levels were highest among patients with HFpEF and lowest among patients with HFrEF; 236.44 (132.89 -432) vs. 38.72 (23.15-67.31) ng/mL respectively (p<0.001). Median NT-proBNP levels, as expected, were significantly higher among patients with HF compared to healthy controls (660 (291 -1000) vs. 92 (78 -102) pg/mL, p<0.001). As a marker of systemic inflammation, hsCRP values, NLR, and PLR did not differ significantly among HF patients and controls. Conclusion GSK3β levels were significantly higher among patients with HF. Also, as the ejection fraction declines, GSK3β levels also reduce, probably as a protective mechanism to prevent further apoptosis and myocyte death.
Resumo Fundamento A glicogênio sintase quinase 3β (GSK3β) é uma enzima que tem papéis na patogênese da insuficiência cardíaca (IC). Tentamos revelar os níveis séricos de GSK3β em tipos de IC. Objetivos Neste estudo, avaliamos os níveis séricos de GSK3β em pacientes com IC. Além disso, tentamos elucidar qualquer possível relação entre os níveis séricos de GSK3β e a gravidade da doença entre três tipos diferentes de pacientes com IC. Métodos Realizamos um estudo prospectivo e inscrevemos 112 pacientes: 50 pacientes no grupo IC com fração de ejeção preservada (ICFEp), 30 pacientes no grupo IC com FE levemente reduzida (ICFEmr) e 32 pacientes no grupo IC com FE reduzida (ICFEr). Também avaliamos 50 controles saudáveis. Exames ecocardiográficos foram realizados. Medimos a GSK-3β sérica e o peptídeo natriurético tipo B N-terminal (NT-proBNP). Medimos os níveis de proteína C-reativa altamente sensível (PCR-as) e calculamos a razão neutrófilo-linfócito (NLR) e a razão plaquetas-linfócitos (PLR) a partir da contagem do hemograma. A significância estatística aceita foi p < 0,05. Resultados Os níveis séricos de GSK3β foram significativamente maiores entre pacientes com IC em comparação com controles saudáveis (níveis medianos de GSK3β; 117,26 (45,39 -223,85) vs 13,91 (5,6 -23,3) ng/mL, p < 0,001). Além disso, os níveis de GSK3β foram maiores entre pacientes com ICFEp e menores entre pacientes com ICFEr; 236,44 (132,89 -432) vs. 38,72 (23,15-67,31) ng/mL, respectivamente (p < 0,001). Os níveis medianos de NT-proBNP, como esperado, foram significativamente maiores entre pacientes com IC em comparação com controles saudáveis (660 (291 -1000) vs. 92 (78 -102) pg/mL, p<0,001). Como um marcador de inflamação sistêmica, os valores de hsCRP, NLR e PLR não diferiram significativamente entre pacientes com IC e controles. Conclusão: Os níveis de GSK3β foram significativamente maiores entre pacientes com IC. Além disso, à medida que a fração de ejeção diminui, os níveis de GSK3β também se reduzem, provavelmente como um mecanismo de proteção para evitar mais apoptose e morte de miócitos.]]></description><identifier>ISSN: 0066-782X</identifier><identifier>EISSN: 1678-4170</identifier><identifier>DOI: 10.36660/abc.20240155i</identifier><language>eng</language><ispartof>Arquivos brasileiros de cardiologia, 2024, Vol.121 (11)</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c79i-5d7d1cc89be6324df4c2b6b1bd69405bcb38bf8013861b02b676b49da92109ba3</cites><orcidid>0000-0003-0681-3267 ; 0000-0001-7081-5799 ; 0000-0003-1251-3148</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,4010,27900,27901,27902</link.rule.ids></links><search><creatorcontrib>Altunbas, Gokhan</creatorcontrib><creatorcontrib>Kaplan, Mehmet</creatorcontrib><creatorcontrib>Duzen, Veysel</creatorcontrib><creatorcontrib>Kaya, Emin Erdem</creatorcontrib><creatorcontrib>Gokdeniz, Hafize Gokce</creatorcontrib><creatorcontrib>Taysi, Seyithan</creatorcontrib><title>Determination of Serum Glycogen Synthase 3 Beta Levels in Patients with Heart Failure, a Novel Marker for Diagnosis and Defining Disease Severity?</title><title>Arquivos brasileiros de cardiologia</title><description><![CDATA[Abstract Background Glycogen synthase kinase 3β (GSK3β) is an enzyme that has roles in the pathogenesis of heart failure (HF). We try to reveal serum GSK3β levels in types of HF. Objectives In this study, we evaluated serum GSK3β levels in HF patients. Also, we tried to elucidate any possible relationship between serum GSK3β levels and disease severity among three different types of HF patients. Methods We performed a prospective study and enrolled 112 patients: 50 patients in heart failure with preserved ejection fraction (HFpEF) group, 30 patients in heart failure with mildly reduced ejection fraction (HFmrEF) group, and 32 patients in heart failure with reduced ejection fraction group (HFrEF). We also evaluated 50 healthy controls. Echocardiographic examinations were performed. We measured serum GSK-3β and N-terminal pro-B-type natriuretic peptide (NT-proBNP). We measured highly sensitive C-reactive protein (hs-CRP) levels and calculated neutrophil-lymphocyte ratio (NLR) platelets-to-lymphocyte ratio (PLR) from the hemogram count. Statistical significance was accepted p < 0.05. Results Serum GSK3β levels were significantly higher among patients with HF compared to healthy controls (median GSK3β levels; 117.26 (45.39 -223.85) vs 13.91 (5.6 -23.3) ng/mL, p<0.001). Also, GSK3β levels were highest among patients with HFpEF and lowest among patients with HFrEF; 236.44 (132.89 -432) vs. 38.72 (23.15-67.31) ng/mL respectively (p<0.001). Median NT-proBNP levels, as expected, were significantly higher among patients with HF compared to healthy controls (660 (291 -1000) vs. 92 (78 -102) pg/mL, p<0.001). As a marker of systemic inflammation, hsCRP values, NLR, and PLR did not differ significantly among HF patients and controls. Conclusion GSK3β levels were significantly higher among patients with HF. Also, as the ejection fraction declines, GSK3β levels also reduce, probably as a protective mechanism to prevent further apoptosis and myocyte death.
Resumo Fundamento A glicogênio sintase quinase 3β (GSK3β) é uma enzima que tem papéis na patogênese da insuficiência cardíaca (IC). Tentamos revelar os níveis séricos de GSK3β em tipos de IC. Objetivos Neste estudo, avaliamos os níveis séricos de GSK3β em pacientes com IC. Além disso, tentamos elucidar qualquer possível relação entre os níveis séricos de GSK3β e a gravidade da doença entre três tipos diferentes de pacientes com IC. Métodos Realizamos um estudo prospectivo e inscrevemos 112 pacientes: 50 pacientes no grupo IC com fração de ejeção preservada (ICFEp), 30 pacientes no grupo IC com FE levemente reduzida (ICFEmr) e 32 pacientes no grupo IC com FE reduzida (ICFEr). Também avaliamos 50 controles saudáveis. Exames ecocardiográficos foram realizados. Medimos a GSK-3β sérica e o peptídeo natriurético tipo B N-terminal (NT-proBNP). Medimos os níveis de proteína C-reativa altamente sensível (PCR-as) e calculamos a razão neutrófilo-linfócito (NLR) e a razão plaquetas-linfócitos (PLR) a partir da contagem do hemograma. A significância estatística aceita foi p < 0,05. Resultados Os níveis séricos de GSK3β foram significativamente maiores entre pacientes com IC em comparação com controles saudáveis (níveis medianos de GSK3β; 117,26 (45,39 -223,85) vs 13,91 (5,6 -23,3) ng/mL, p < 0,001). Além disso, os níveis de GSK3β foram maiores entre pacientes com ICFEp e menores entre pacientes com ICFEr; 236,44 (132,89 -432) vs. 38,72 (23,15-67,31) ng/mL, respectivamente (p < 0,001). Os níveis medianos de NT-proBNP, como esperado, foram significativamente maiores entre pacientes com IC em comparação com controles saudáveis (660 (291 -1000) vs. 92 (78 -102) pg/mL, p<0,001). Como um marcador de inflamação sistêmica, os valores de hsCRP, NLR e PLR não diferiram significativamente entre pacientes com IC e controles. Conclusão: Os níveis de GSK3β foram significativamente maiores entre pacientes com IC. Além disso, à medida que a fração de ejeção diminui, os níveis de GSK3β também se reduzem, provavelmente como um mecanismo de proteção para evitar mais apoptose e morte de miócitos.]]></description><issn>0066-782X</issn><issn>1678-4170</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kMtOwzAQRS0EEqWwZT0fQIofiZOsELS0RSoPqV2wi2xn0hpaB9kuKL_BFxMeYjXSnXvP4hByzuhISCnppdJmxClPKcsye0AGTOZFkrKcHpIBpVImecGfj8lJCC-Ucp6LbEA-JxjR76xT0bYO2gaW6Pc7mG07067RwbJzcaMCgoAbjAoW-I7bANbBUz9BFwN82LiBOSofYarsdu_xAhQ8tH0R7pV_RQ9N62Fi1dq1wQZQroYJNtZZt-7jgN_8ZQ_2NnZXp-SoUduAZ393SFbT29V4niweZ3fj60Vi8tImWZ3XzJii1CgFT-smNVxLzXQty5Rm2mhR6KagTBSSadr_cqnTslYlZ7TUSgzJ6BdrfBuCx6Z683anfFcxWv0IrXqh1b9Q8QWke2tl</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Altunbas, Gokhan</creator><creator>Kaplan, Mehmet</creator><creator>Duzen, Veysel</creator><creator>Kaya, Emin Erdem</creator><creator>Gokdeniz, Hafize Gokce</creator><creator>Taysi, Seyithan</creator><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-0681-3267</orcidid><orcidid>https://orcid.org/0000-0001-7081-5799</orcidid><orcidid>https://orcid.org/0000-0003-1251-3148</orcidid></search><sort><creationdate>2024</creationdate><title>Determination of Serum Glycogen Synthase 3 Beta Levels in Patients with Heart Failure, a Novel Marker for Diagnosis and Defining Disease Severity?</title><author>Altunbas, Gokhan ; Kaplan, Mehmet ; Duzen, Veysel ; Kaya, Emin Erdem ; Gokdeniz, Hafize Gokce ; Taysi, Seyithan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c79i-5d7d1cc89be6324df4c2b6b1bd69405bcb38bf8013861b02b676b49da92109ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Altunbas, Gokhan</creatorcontrib><creatorcontrib>Kaplan, Mehmet</creatorcontrib><creatorcontrib>Duzen, Veysel</creatorcontrib><creatorcontrib>Kaya, Emin Erdem</creatorcontrib><creatorcontrib>Gokdeniz, Hafize Gokce</creatorcontrib><creatorcontrib>Taysi, Seyithan</creatorcontrib><collection>CrossRef</collection><jtitle>Arquivos brasileiros de cardiologia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Altunbas, Gokhan</au><au>Kaplan, Mehmet</au><au>Duzen, Veysel</au><au>Kaya, Emin Erdem</au><au>Gokdeniz, Hafize Gokce</au><au>Taysi, Seyithan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determination of Serum Glycogen Synthase 3 Beta Levels in Patients with Heart Failure, a Novel Marker for Diagnosis and Defining Disease Severity?</atitle><jtitle>Arquivos brasileiros de cardiologia</jtitle><date>2024</date><risdate>2024</risdate><volume>121</volume><issue>11</issue><issn>0066-782X</issn><eissn>1678-4170</eissn><abstract><![CDATA[Abstract Background Glycogen synthase kinase 3β (GSK3β) is an enzyme that has roles in the pathogenesis of heart failure (HF). We try to reveal serum GSK3β levels in types of HF. Objectives In this study, we evaluated serum GSK3β levels in HF patients. Also, we tried to elucidate any possible relationship between serum GSK3β levels and disease severity among three different types of HF patients. Methods We performed a prospective study and enrolled 112 patients: 50 patients in heart failure with preserved ejection fraction (HFpEF) group, 30 patients in heart failure with mildly reduced ejection fraction (HFmrEF) group, and 32 patients in heart failure with reduced ejection fraction group (HFrEF). We also evaluated 50 healthy controls. Echocardiographic examinations were performed. We measured serum GSK-3β and N-terminal pro-B-type natriuretic peptide (NT-proBNP). We measured highly sensitive C-reactive protein (hs-CRP) levels and calculated neutrophil-lymphocyte ratio (NLR) platelets-to-lymphocyte ratio (PLR) from the hemogram count. Statistical significance was accepted p < 0.05. Results Serum GSK3β levels were significantly higher among patients with HF compared to healthy controls (median GSK3β levels; 117.26 (45.39 -223.85) vs 13.91 (5.6 -23.3) ng/mL, p<0.001). Also, GSK3β levels were highest among patients with HFpEF and lowest among patients with HFrEF; 236.44 (132.89 -432) vs. 38.72 (23.15-67.31) ng/mL respectively (p<0.001). Median NT-proBNP levels, as expected, were significantly higher among patients with HF compared to healthy controls (660 (291 -1000) vs. 92 (78 -102) pg/mL, p<0.001). As a marker of systemic inflammation, hsCRP values, NLR, and PLR did not differ significantly among HF patients and controls. Conclusion GSK3β levels were significantly higher among patients with HF. Also, as the ejection fraction declines, GSK3β levels also reduce, probably as a protective mechanism to prevent further apoptosis and myocyte death.
Resumo Fundamento A glicogênio sintase quinase 3β (GSK3β) é uma enzima que tem papéis na patogênese da insuficiência cardíaca (IC). Tentamos revelar os níveis séricos de GSK3β em tipos de IC. Objetivos Neste estudo, avaliamos os níveis séricos de GSK3β em pacientes com IC. Além disso, tentamos elucidar qualquer possível relação entre os níveis séricos de GSK3β e a gravidade da doença entre três tipos diferentes de pacientes com IC. Métodos Realizamos um estudo prospectivo e inscrevemos 112 pacientes: 50 pacientes no grupo IC com fração de ejeção preservada (ICFEp), 30 pacientes no grupo IC com FE levemente reduzida (ICFEmr) e 32 pacientes no grupo IC com FE reduzida (ICFEr). Também avaliamos 50 controles saudáveis. Exames ecocardiográficos foram realizados. Medimos a GSK-3β sérica e o peptídeo natriurético tipo B N-terminal (NT-proBNP). Medimos os níveis de proteína C-reativa altamente sensível (PCR-as) e calculamos a razão neutrófilo-linfócito (NLR) e a razão plaquetas-linfócitos (PLR) a partir da contagem do hemograma. A significância estatística aceita foi p < 0,05. Resultados Os níveis séricos de GSK3β foram significativamente maiores entre pacientes com IC em comparação com controles saudáveis (níveis medianos de GSK3β; 117,26 (45,39 -223,85) vs 13,91 (5,6 -23,3) ng/mL, p < 0,001). Além disso, os níveis de GSK3β foram maiores entre pacientes com ICFEp e menores entre pacientes com ICFEr; 236,44 (132,89 -432) vs. 38,72 (23,15-67,31) ng/mL, respectivamente (p < 0,001). Os níveis medianos de NT-proBNP, como esperado, foram significativamente maiores entre pacientes com IC em comparação com controles saudáveis (660 (291 -1000) vs. 92 (78 -102) pg/mL, p<0,001). Como um marcador de inflamação sistêmica, os valores de hsCRP, NLR e PLR não diferiram significativamente entre pacientes com IC e controles. Conclusão: Os níveis de GSK3β foram significativamente maiores entre pacientes com IC. Além disso, à medida que a fração de ejeção diminui, os níveis de GSK3β também se reduzem, provavelmente como um mecanismo de proteção para evitar mais apoptose e morte de miócitos.]]></abstract><doi>10.36660/abc.20240155i</doi><orcidid>https://orcid.org/0000-0003-0681-3267</orcidid><orcidid>https://orcid.org/0000-0001-7081-5799</orcidid><orcidid>https://orcid.org/0000-0003-1251-3148</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0066-782X |
ispartof | Arquivos brasileiros de cardiologia, 2024, Vol.121 (11) |
issn | 0066-782X 1678-4170 |
language | eng |
recordid | cdi_crossref_primary_10_36660_abc_20240155i |
source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; PubMed Central Open Access |
title | Determination of Serum Glycogen Synthase 3 Beta Levels in Patients with Heart Failure, a Novel Marker for Diagnosis and Defining Disease Severity? |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T19%3A09%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-crossref&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determination%20of%20Serum%20Glycogen%20Synthase%203%20Beta%20Levels%20in%20Patients%20with%20Heart%20Failure,%20a%20Novel%20Marker%20for%20Diagnosis%20and%20Defining%20Disease%20Severity?&rft.jtitle=Arquivos%20brasileiros%20de%20cardiologia&rft.au=Altunbas,%20Gokhan&rft.date=2024&rft.volume=121&rft.issue=11&rft.issn=0066-782X&rft.eissn=1678-4170&rft_id=info:doi/10.36660/abc.20240155i&rft_dat=%3Ccrossref%3E10_36660_abc_20240155i%3C/crossref%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |